JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Recently approved drug for Asthma management.

Sarila[1], Dr. Dharmendra Ahuja[2], Shilpa Thakur[3], Anamika Verma,[4] Anshul Saini[5]

Abstract

In this review, we discuss a recently approved drug for asthma management. There are lots of publications on asthma that identify the treatment of asthma but some researchers doubt their work. this paper includes the introduction of an asthma study and a combo of two new medications for asthma. &Classification of asthma, Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin a cytokine generated from epithelial cells that is linked to the development of asthma more research is needed to determine the safety and effectiveness of Tezepelumab in treating individuals with severe uncontrolled asthma.

Keywords: Management, Tezepelumab, Monoclonal, Cytokine, lymphopoetin.

Introduction

Asthma is currently treated with a wide range of alternatives, and researchers are always looking for new approaches. You can find out about the most recent and upcoming treatments if you have asthma. Certain kinds of asthma can be treated with some of the more recent methods. Biologic therapy can improve your breathing if you use an inhaler but still have asthma symptoms. it works by targeting different sections of your body, any biologic therapy that is most appropriate for you will be administered via injection by your doctors.

Cough, wheezing, breathing difficulties, and tightness in the chest are symptoms of asthma. A chronic heterogeneous illness of the lower airways marked by ongoing inflammation and hyperreactivity of the airways. Asthma has complicated pathogenesis over the last thirty years, a deeper comprehension of the various aspects of asthma that are visible phenotypes and the mechanisms behind them endotypes has led to the development of improved diagnostics and therapeutics instruments to support personalized and stratified interventions based on differences in responses to different therapeutics approaches. (Chung & Agache et.al) furthermore, asthma development, heterogeneity in phenotyping, and steroid responsiveness are influenced by genetic polymorphisms, environmental variables, and epigenetic factors. (Olafsdottir&KimJ, KimY-C et al.) asthma control and exacerbations can be enhanced by environmental interventions and exposure management. (Celebi et.al) asthma is becoming more common and more common in occurrence yet consistent treatment of inhaled corticosteroids lowers mortality. (PapiA, BornaE et.al) to better control symptoms and exacerbations in patients with severe asthma and to prevent adverse responses from oral corticosteroid administration, new medicines, and therapeutic targets are needed.

Classification of asthma

Based on the molecular characteristics, phenotypes, and time of illness start, several categories of asthma have been developed many of them feature overlaps and severs and chronic asthma defies all of these classifications.

Phenotypes asthma

Since asthma is a heterogeneous illness, it has been suggested that groups of asthma patients can be distinguished using asthma phenotypes. Some but not all asthma patients share characteristics known as phenotypes which might include clinical, physiological laboratory, and or molecular data. personalized treatment is one benefit of grouping people into distinct asthma profiles.

There may be differences between asthma that develops in childhood and adulthood in terms of sex ratio, exacerbation triggers comorbidities severity, and genetics. (Bush A, Busse W, Polidori M et al) more severe or long-lasting asthma has been linked to worsened lung function, higher airway hyperresponsiveness sensitization as shown by raised serum Ige levels, and older age of diagnosis.in cases of childhood-onset asthma (Fitzpatrick Dodge et al) when compared to childhood-onset asthma adult-onset asthma is generally more severe has a lower rate of remission and is less typically linked to allergies. (De Marco, Shaaban et.al) recently genome-wide association studies were used to compare the genetic architecture of adult-onset and childhood-onset asthma. The result showed that overall tge genetic risk for adult-onset asthma is smaller than the genetic risk for childhood-onset asthma, but it is still largely a subset of the former in the childhood-onset GWAS, but not in the adult-onset GWAS, the 17q12-23 region, which has shown the highest link with asthma in several previous GWASs was extreamlysignificant. Conversely, there was a high correlation found between the HLA on chromosome 6 and asthma that manifested in childhood and adulthood. (Pividori M et al) according to a different study, there may be differences in the inflammatory pathways and gene expression patterns between severe asthma in children and adults based on variations in gene expression across multiple tissues (Hekking P, P et al) together, these findings imply that childhood-onset asthma is more genetically predisposed, while adult-onset asthma is more influenced by environmental exposure, with immune mechanisms playing a role in both. Five phenotypic clusters of severe asthma have been found by the severe asthma research programme comprising two clusters in children and three in adults. Age of onset, lung infection, medication use, health care utilization, and comorbidities, are factors that set these clusters that set these clusters apart. (Fitzpatrick A.M Moore W.C et.al) to determine additional characteristics that indicate severe asthma clusters and those who are likely to respond to corticosteroid treatment, unsupervised clustering using machine learning has been applied to the SARP Cohort. (Wu W. WU&W Bang et al) patients with severe asthma and frequent exacerbations within the SARP cohort have been found to have higher BMI, bronchodilator, responsiveness, and blood eosinophil count. (Denlinger L.C.et al) a different group of patients reported that frequent exacerbation had higher fractional exacerbation of nitric oxide and a history of smoking. (Kupczy K.M et al) other studies that evaluated different phenotypes in severe asthma include the severe and uncontrolled asthma registry from Italy and unbiased biomarkers in the prediction of respiratory disease outcomes. these studies have contributed to our understanding of asthma phenotype and endotypes even though SARP phenotypes have been crucial in identifying features that separate distinct clusters of patients with asthma the phenotypes cannot clinical decision making.

Endotype asthma

Endotypes are subsets of persons based on unique functional or pathologic systems, whereas phenotypes concentrate on observed or measured qualities. Multitiomic characterization is often included, with asthma endotypes being characterized based on genomic, transcriptomic, epigenomic, proteomic, and metabolomic profiles. Furthermore, phenotypes and endotypes can be connected by immunological profiling. Th2 inflammation has mainly focused on IgE levels and blood eosinophils count and has been associated with a subset of individuals with severe asthma. According to a retrospective review of asthma patients, those with low airway reversibility have better disease control and strong biomarkers of Th2 immune responses as compared to those with high airway reversibility when using bronchodilators (Busse. W.W et al) mepolizumab an anti-IL- 5 antibody has also been used to profile patients in the past. BMI, blood eosinophil count, and airway reversibility were the predictors of response. Few research has gone beyond assessing Th2 inflammation in the case of severe asthma. One study found that in patients with stable asthma, high levels of soluble ST2, THE IL-33 receptor. predicted a severe asthma exacerbation within three months. (Watanabe M et al). all things considered, patients with persistent and severe asthma who have undergone supervised and unsupervised phenotyping appear to be more obese and to have greater Th2 inflammatory markers. Not surprisingly, corticosteroid use is higher and exacerbations occur more frequently in persistent and severe asthma subtypes. There are more than 60 genetic loci linked to asthma. (Pividori M et al) severe asthma has been connected to a few of these. Five loci linked to severe asthma exacerbations have been found by GWASs in both children and adults. Additionally, other genes are involved in immunological responses, such as IL33, IL1 RL1, and CDR3. (Bonnelykke K, Wan Y.I et al) have been implicated. 24 loci were linked to moderate to severe asthma according to a GWAS, and additional research revealed that one of the risk genes was linked to higher mucin production. (Shrine N. et al) numerous research studies have looked into the role of gene expression in severe and have been carried out in a variety of cell types, such as BAL, whole blood, and sputum. And airways epithelial cells. It is crucial to understand that gene expression varies depending on the tissue. (Hekking, Bigler, Modena, Singhania A& Hekking Rossio C, et al) additionally, some research has contrasted variations in gene expression responses following particular therapies, it should come as no surprise that several gene expression patterns have been found and that these signatures suggest that a variety of processes contribute to severe and persistent asthma, numerous mechanisms suggest modified immune responses. Few studies have looked at proteomics in severe asthma. Even though sputum proteomic has been a popular field of study in asthma. Sputum supernatants from patients with severe asthma who smoked and those who were never smokers or ex-smokers were compared in the biggest proteome study of patients

with severe asthma and different proteome studies of patients with severe asthma. And different proteomic patterns were seen across all groups. In this study sputum from smokers had higher amounts of colony-stimulating factors 2 proteins. And sputum from ex-smokers had higher levels of CXCL8 neutrophil and azurocidin. (Takahashi K et al). both in children and adults, metabolic abnormalities between chronic and severe asthma have been described. However, the relevance of these findings is unclear because no single pathway was identified, and the results are confounded by a high probability of corticosteroid use. (Fitzpatrick, Park, Reinke S.N et al). furthermore, several clinical phenotypes have been linked to the airway microbiome in patients with severe asthma, such as elevated levels of Pseudomonadaceae and Enterobacteriaceae in the sputum of these patients and corticosteroid responsiveness with actinobacteria in bronchial brushing. (Huang YJ. Lin Millares L et al) when taken as a whole genotyping in svere asthma has brought attention to the important role that various immunological systems play. Clarification of the pathology of severe asthma is anticipated to come from further integration of the many observations from different types.

Contemporary studies of asthmatic drugs.

The U.S. Food and Drug Administration authorized air supra as adults with asthma now have new drugs to turn to for relief. Combining budesonide and albuterol in one medication is a first. When used as needed, air supra helps individuals with asthma who are 18 years of age and older avoid bronchoconstriction and lower their chance of having an asthma attack. Not only is this drug authorized in the US. But it is also the first to use an inhaled corticosteroid to treat rather than control asthma symptoms. before approving it, the FDA conducted a randomized, double-blind, controlled research with patients who had moderate to severe asthma to see how well the medication reduced severe asthma attacks. Patients in the trial were randomized to receive either albuterol alone or air supra. At least 24 weeks of treatment were given to the patients. The duration between an emergency department visit that resulted in the need for steroids of hospitalization for at least 24 hours, or the first severe asthma episode that required systemic corticosteroid for at least three days, was examined by the researchers. When compared to patients receiving only albuterol, adult patients treated with airsupra experienced a 28% decrease in the likelihood of severe asthma episodes. The FDA advises patients not to utilize more than six doses, or a total of 12 inhalations, in 24 hours. Use of the medication should be cautious in those with hyperthyroidism, diabetes, convulsive disorders, cardiovascular problems, and consequences of ketoacidosis. Speaking difficulties, a cough, headache, and oral yeast infection were the most frequent side effects reported by people taking Airspura.

Airsupra

The US has authorized AIRSUPTATM albuterol/budesonide, formerly known as PT027, for the prevention or as-needed treatment of bronchoconstriction and to lower the risk of exacerbations in individuals with asthma who are 18 years of age or older. based on the outcomes of the MANDALA and DENALI phase III trials, the Food and Drug Administration approved the medication. (Papi A, Chipps et.al) as a rescue drug for moderate to severe asthma airspura dramatically decreased the likelihood of severe exacerbation in MANDALA patients are compared to albuterol when taken in response to symptoms. One significantly, at the permitted dose of 180mcg albuterol/ 160 mcg budesonide, AIRSUPRA showed a significant reduction in the secondary endpoint of mean annualized total systemic corticosteroid exposure when compared to albuterol. One when compared to the individual component of albuterol and budesonide in DENALI, AIRSPURA dramatically improved lung function in patients with mild to moderate asthma. (Chipps et.al)

AIRSPURA is an industry-leading pressurized metered dose inhaler. Fixed dose combination rescue medication that contains albuterol a short-acting beta 2agonist and budesonide an anti-inflammatory inhaler in the United States. AIRSUPRA is being developed by the AstraZeneca-based company Avillion. People with asthma are at risk of severe exacerbations regardless of their disease severity or level of control. Stated (Bradley. E Chipps et.al) past president of the America College of Allergy and Respiratory Illness Centre in Sacramento, US.

The current generation of albuterol rescue inhalers reduces asthma's acute symptoms but not its underlying inflammation. With the approval of AIRSUPRA adults with asthma in the US can now treat their condition to reduce inflammation and control symptoms for the first time. With patients experiencing over 10 million asthma exacerbations annually in the US and uncontrolled asthma except to cost the US economy billions of dollars in direct medical costs alone over the next 20 years, today's positive decision is good news for those adults with asthma who make up more than 80% of asthma patients in the US stated mene Panglao’s executive vice president, Bio pharmaceuticals R& D AstraZeneca. The significant new rescue medication AIRSUPRA which lowers the risk of asthma exacerbation will be available for doctors to prescribe to their patients.

A chronic inflammatory respiratory illness, asthma affects up to 262 million people globally and has a wide range of symptoms (The Global et.al) more than 21 million adults in the US suffer from asthma, accounting for more than

80% of all asthma sufferers. (CDC.et.al) in the US there are 8.5 million exacerbations among adults annually. (CDC et.al) The US economy will lose $300 billion in 2018 due to uncontrolled asthma in just the first 20 years of direct medical costs alone. (Yaghoobi et.al) in both trials, the safety and tolerability of AIRSUPRA were in line with the established profiles of the constituents (Papi A, Chipps et al) with headache, oral candidiasis, coughing, and dysphonia being the most frequent adverse events.

Tezspire

A first-in-class human monoclonal antibody, Tezspire targets, and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic, and other types of airway's inflammation associated with severe asthma. (CorrenJ, VarricchiG et.al) TSLP is released in response to multiple triggers associated with asthma exacerbation, including allergens, viruses, and other airborne particles. Patients with asthma have higher expression of TSLP in their airways and this expression has been linked to the severity of the condition (CorrenJ, Li Y, et.al) inhibiting TSLP immune cells may prevent from releasing pro-inflammatory cytokinin which might lead to better asthma control and a reduction in asthma flareups. (Corren, J&Li Y, et.al) Tezspire helps treat a wide range of severe asthma patients by acting at the top of the cascade which helps reduce inflammation at its source.

Tezspire approval came after the FDA gave it a priority review, considering data from the PATHFINDER clinical study program. The application contained data from the major NAVIGATOR phase 3 trial, which showed that when Tezspire was added to standard medication, patients with severe asthma showed superiority over placebo across all primary and important secondary endpoints. (Menzies et.al) according to David M. Reese, M.D. executive vice president of research and development at Amengn, the FDA, approval signifies that first-time patients and their physicians will have a biological option for severe asthma without phenotypic limitation and irrespective of biomarker levels. Everybody is affected differently by asthma which is a chronic inflammatory illness that is complicated and has the potential to treat a large group of individuals with severe asthma, particularly those who have historically lacked access to effective treatment alternatives by acting at the top of the inflammatory cascade which helps to reduce the inflammation that triggers asthma attacks at the source.

Tezspire is first- a class biologic for severe asthma that targets the epithelial cytokines thyme stromal lymphopoietin at the top of the inflammatory cascade. (CorrenJ et al). throughout phase 2 and 3 clinical trials, which include a large population of patients with severe asthma regardless of important biomarkers like blood eosinophil counts allergic status, and fractional exhaled nitric oxide, it is the first and only biologic to consistently and significantly reduce asthma exacerbation. (Menzies&CorrenJ et al.) Tez spire is the first and only biologic for severe asthma without a biomarker constraint of phenotypic restriction allergic or eosinophilic on its approved label,(Hanania NA, Wenzel S et.al) professor Andrew Menzies- Grow, the principal investigator of the NAVIGATOR trial and director of the lung division at Royal Brompton Hospital in London UK, stated that many patients still experience frequent exacerbations, an increased risk of hospitalization, and a significantly reduced quality of life due to the complex and heterogeneous nature of severe asthma even with recent advancements Tezspire represents a much needed new treatment for the many patients who remains understand and continue struggle with severe uncontrolled asthma.

Conclusion.

Asthma research is one of the fields that is developing the fastest, with up to 9000 articles produced per year. The majority of the cutting-edge discoveries in the last year have been made in the fields of precision medicine endotypes and phenotypes, biomarkers edge therapies like biologicals, and real-world research. In many chronic illnesses the personalised and stratified approaches to patient care and focused therapies are the way of the future. The primary areas of focus for enhancing patients' treatments going forward include learning, more about the molecular and finding new biomarkers.

Reference

1.Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. *Allergy* 2019; **74**(9): 1649–1659.

2. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, Regio types, and other types of allergic diseases. *J Clin Invest.* 2019; **129**(4): 1493–1503.

3. Olafsdottir TA, Theodors F, Bjarnadottir K, et al. Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis. *Nat Commun.* 2020; **11**(1): 393.

4. Guo Y, Moon J-Y, Laurie CC, et al. Genetic predisposition to obesity is associated with asthma in US Hispanics/Latinos: results from the Hispanic Community Health Study/Study of Latinos. *Allergy* 2018; **73**(7): 1547–1550.

5. D'Amato G, Annesi-Maesano I, Cecchi L, D'Amato M. Latest news on the relationship between thunderstorms and respiratory allergy, severe asthma, and deaths for asthma. *Allergy* 2019; **74**(1): 9–

6. Kim J, Kim Y-C, Ham J, et al. The effect of air pollutants on airway innate immune cells in patients with asthma. *Allergy* 2020; **75**(9): 2372–2376.

7. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in epithelial barrier dysfunction. *J Allergy Clin Immunol.* 2020; **145**(6): 1517–1528.

8. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. *The Lancet.* 2018; **391**(10122): 783–800.

9. Borna E, Nwaru BI, Bjerg A, et al. Changes in the prevalence of asthma and respiratory symptoms in western Sweden between 2008 and 2016. *Allergy* 2019; **74**(9): 1703–1715.

10. https://www.drugs.com/news/fda-approves-new-two-combo-medicine-asthma-110055.html

11 Chipps BE, et.al. Efficacy and safety of albuterol/budesonidept027 in mild to moderate asthma: Result of the DENALI study. Am J Respir Crit Care Med 2022,205 A3414, Abstract. Available at : https://doi.org/10.1164/ajrccm...etingAbstracts A3414 [Last accessed: November 2022].

12. The Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: http://globalasthmareport.org/index.html[Last accessed: November 2022].

13. CDC. Most Recent National Asthma Data. [Online]/ Available at: https://www.cdc.gov/asthma/mos...onal_asthma_data.htm. [Last accessed: November 2022].

14. Yaghoubi M, *et al*. The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. *Am J Respir Crit Care Med*. 2019; 200 (9): 1102-1112.

15. Menzies-Gow A, *et al*. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. *N Engl J Med*. 2021; 384:1800-1809. DOI: 10.1056/NEJMoa2034975.

16. Corren J, et al. Tezepelumab in adults with uncontrolled asthma [supplementary appendix

updated April 18, 2019]. *N Engl J Med*. 2017; 377: 936-946.

17. Hanania NA, *et al*. Omalizumab in severe allergic asthma inadequately controlled with

standard therapy: a randomized trial. *Ann Intern Med*. 2011;154 (9): 573-82.

18. Wenzel S, *et al*. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomized double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet.* 2016 Jul 2;388(10039):31-44

19.Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. *Front Immunol.* 2018; 9: 1595.

20. Li Y, et al. Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. *J Immunol*. 2018; 200: 2253–2262.

21 Bush A., Menzies-Gow A. Phenotypic differences between pediatric and adult asthma. *Proc Am Thorac Soc.* 2009;6(8):712–719. [PubMed] [Google Scholar]

22. Busse W., Banks-Schlegel S.P., Larsen G.L. Childhood- versus adult-onset asthma. *Am J Respir Crit Care Med.* 1995;151(5):1635–1639. [PubMed] [Google Scholar]

23Pividori M., Schoettler N., Nicolae D.L., Ober C., Im H.K. Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies. *Lancet Respir Med.* 2019;7(6):509–522. [PMC free article] [PubMed] [Google Scholar]

24Fitzpatrick A.M., Teague W.G. Severe asthma in children: insights from the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. *Pediatr Allergy Immunol Pulmonol.* 2010;23(2):131–138. [PMC free article] [PubMed] [Google Scholar]

25 Dodge R., Martinez F.D., Cline M.G., Lebowitz M.D., Burrows B. Early childhood respiratory symptoms and the subsequent diagnosis of asthma. *J Allergy Clin Immunol.* 1996;98(1):48–54. [PubMed] [Google Scholar]

26 De Marco R., Locatelli F., Cerveri I. Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy. *J Allergy Clin Immunol.* 2002;110(2):228–235. [PubMed] [Google Scholar]

27Shaaban R., Zureik M., Soussan D. Rhinitis and onset of asthma: a longitudinal population-based study. *Lancet.* 2008;372(9643):1049–1057. [PubMed] [Google Scholar]

28Hekking P.P., Loza M.J., Pavlidis S. Pathway discovery using transcriptomic profiles in adult-onset severe asthma. *J Allergy Clin Immunol.* 2018;141(4):1280–1290. [PubMed] [Google Scholar]

29Fitzpatrick A.M., Teague W.G., Meyers D.A. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. *J Allergy Clin Immunol.* 2011;127(2):382–389. e381-e313. [PMC free article] [PubMed] [Google Scholar]

30. Moore W.C., Meyers D.A., Wenzel S.E. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med.* 2010;181(4):315–323. [PMC free article] [PubMed] [Google Scholar]

31 Wu W., Bleecker E., Moore W. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. *J Allergy Clin Immunol.* 2014;133(5):1280–1288. [PMC free article] [PubMed] [Google Scholar]

32 Wu W., Bang S., Bleecker E.R. Multiview cluster analysis identifies variable corticosteroid response phenotypes in severe asthma. *Am J Respir Crit Care Med.* 2019;199(11):1358–1367. [PMC free article] [PubMed] [Google Scholar]

33 Denlinger L.C., Phillips B.R., Ramratnam S. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. *Am J Respir Crit Care Med.* 2017;195(3):302–313. [PMC free article] [PubMed] [Google Scholar]

34 Kupczyk M., ten Brinke A., Sterk P.J. Frequent exacerbators--a distinct phenotype of severe asthma. *Clin Exp Allergy.* 2014;44(2):212–221. [PubMed] [Google Scholar]

35Busse W.W., Holgate S.T., Wenzel S.W. Biomarker profiles in asthma with high vs low airway reversibility and poor disease control. *Chest.* 2015;148(6):1489–1496. [PMC free article] [PubMed] [Google Scholar]

36Ortega H., Li H., Suruki R., Albers F., Gordon D., Yancey S. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. *Ann Am Thorac Soc.* 2014;11(7):1011–1017. [PubMed] [Google Scholar]

37 Watanabe M., Nakamoto K., Inui T. Serum sST2 levels predict severe exacerbation of asthma. *Respir Res.* 2018;19(1):169. [PMC free article] [PubMed] [Google Scholar]

38Bonnelykke K., Sleiman P., Nielsen K. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. *Nat Genet.* 2014;46(1):51–55. [PubMed] [Google Scholar]

39Wan Y.I., Shrine N.R., Soler Artigas M. Genome-wide association study to identify genetic determinants of severe asthma. *Thorax.* 2012;67(9):762–768. [PubMed] [Google Scholar]

40Shrine N., Portelli M.A., John C. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. *Lancet Respir Med.* 2019;7(1):20–34. [PMC free article] [PubMed] [Google Scholar]

41Bigler J., Boedigheimer M., Schofield J.P.R. A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts. *Am J Respir Crit Care Med.* 2017;195(10):1311–1320. [PubMed] [Google Scholar]

42 Modena B.D., Bleecker E.R., Busse W.W. Gene expression correlated with severe asthma characteristics reveals heterogeneous mechanisms of severe disease. *Am J Respir Crit Care Med.* 2017;195(11):1449–1463. [PMC free article] [PubMed] [Google Scholar]

43Singhania A., Rupani H., Jayasekera N. Altered epithelial gene expression in peripheral airways of severe asthma. *PLoS One.* 2017;12(1) [PMC free article] [PubMed] [Google Scholar]

44. Hekking P.P., Loza M.J., Pavlidis S. Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. *Eur Respir J.* 2017;50(3) [PubMed] [Google Scholar]

45. Rossios C., Pavlidis S., Hoda U. Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. *J Allergy Clin Immunol.* 2018;141(2):560–570. [PubMed] [Google Scholar]

46. Takahashi K., Pavlidis S., Ng Kee Kwong F. Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. *Eur Respir J.* 2018;51(5) [PubMed] [Google Scholar]

47 Fitzpatrick A.M., Park Y., Brown L.A., Jones D.P. Children with severe asthma have unique oxidative stress-associated metabolomic profiles. *J Allergy Clin Immunol.* 2014;133(1):258–261. e251-e258. [PMC free article] [PubMed] [Google Scholar]

48Park Y.H., Fitzpatrick A.M., Medriano C.A., Jones D.P. High-resolution metabolomics to identify urine biomarkers in corticosteroid-resistant asthmatic children. *J Allergy Clin Immunol.* 2017;139(5):1518–1524.e1514. [PubMed] [Google Scholar]

49. Reinke S.N., Gallart-Ayala H., Gomez C. Metabolomics analysis identifies different metabotypes of asthma severity. *Eur Respir J.* 2017;49(3) [PMC free article] [PubMed] [Google Scholar]

50Huang Y.J., Nariya S., Harris J.M. The airway microbiome in patients with severe asthma: associations with disease features and severity. *J Allergy Clin Immunol.* 2015;136(4):874–884. [PMC free article] [PubMed] [Google Scholar]

5.1Li N., Qiu R., Yang Z. Sputum microbiota in severe asthma patients: relationship to eosinophilic inflammation. *Respir Med.* 2017;131:192–198. [PubMed] [Google Scholar]

52. Millares L., Bermudo G., Perez-Brocal V. The respiratory microbiome in bronchial mucosa and secretions from severe IgE-mediated asthma patients. *BMC Microbiol.* 2017;17(1):20. [PMC free article] [PubMed] [Google Scholar]